Projects / Programmes
Genetic and radioisotopic methods in diagnosis and therapy of thyroid carcinoma
| Code |
Science |
Field |
Subfield |
| 3.04.00 |
Medical sciences |
Oncology |
|
| Code |
Science |
Field |
| B725 |
Biomedical sciences |
Diagnostics |
| B200 |
Biomedical sciences |
Cytology, oncology, cancerology |
| B145 |
Biomedical sciences |
Nuclear medicine, radiobiology |
thyroid carcinoma, genetic testing, mutations, RET proto-oncogen, prophylactic thyroidectomy, radioiodine therapy, prognosis, rhTSH
Researchers (11)
Organisations (1)
| no. |
Code |
Research organisation |
City |
Registration number |
No. of publicationsNo. of publications |
| 1. |
0302 |
Institute of Oncology Ljubljana |
Ljubljana |
5055733000 |
15,468 |
Abstract
Thyroid carcinoma is not biologicaly homogenous. In our prospective study, the patients and their first-degree relatives will be genetically tested, to identify the gene carriers of germline RET proto-oncogene mutation at a clinically asymptomatic stage of medullary thyroid carcinoma, in order perform prophylactic thyroidectomy in them. Our hypothesis is that some mutations of RET proto-oncogene are correlated with more aggressive clinical outcome of medullary carcinoma. Another aim of our study is to analyze correlation between different RET proto-oncogene mutations and possible appearance of multiple endocrine neoplasms. Earlier detection and treatment considerably improve the prognosis of patients with medullary carcinoma and of mutant gene carriers. It results in less aggressive treatment which is also less expensive.
In our retrospective study, we will perform multivariate analysis in order to find out if more extensive thyroid surgery and common radioablation were reasons for longer survival of patients with Hürthle cell carcinoma in comparison to the survival of those with follicular carcinoma.
Till now, it was not possible to use radioiodine in the treatment of patients with thyroid carcinoma and distant metastases in whom withdrawal of thyroid hormone therapy was contraindicated. In our prospective study, we will treat with recombinant human TSH and radioiodine patients: 1) with distant metastases in whom withdrawal of thyroid hormone therapy is contraindicated, and 2) in whom tumor progressed during endogenous elevation of TSH concentration. Our hypothesis is that the treatment with recombinant human TSH and radioiodine may be effective in metastatic follicular or papillary carcinoma. Our purpose is also to find out which dose of radioiodine was effective.
